We rank companies based on fund manager, research analyst and news sentiment
BIVI stock icon

BioVie, Inc. Common Stock
BIVI

$0.49
0.67%
 

About: BioVie Inc is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 18

0
Funds holding %
of 6,474 funds
Analysts bullish %
0
News positive %
of 20 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

188% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 8

0.05% more ownership

Funds ownership: 4.74% [Q3] → 4.79% (+0.05%) [Q4]

9% less funds holding

Funds holding: 57 [Q3] → 52 (-5) [Q4]

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

62% less capital invested

Capital invested by funds: $5.95M [Q3] → $2.28M (-$3.67M) [Q4]

73% less call options, than puts

Call options by funds: $243K | Put options by funds: $891K

Research analyst outlook

1 Wall Street Analyst provided 1 year price forecasts over the past 6 months

Low target
$5
915%
upside
Avg. target
$5
915%
upside
High target
$5
915%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Oppenheimer
Jay Olson
915%upside
$5
Outperform
Maintained
30 Nov 2023

Financial journalist opinion

Based on 20 articles about BIVI published over the past 30 days